09 August 2025 : Review article
Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment
Andrzej Silczuk
ADEF 1, Robert J. Madejek BCDF 1*, Tytus Koweszko BCDEF 1, Paulina Mularczyk-Tomczewska BF 2, Ewelina Adamska BEF 1, Mariusz Gujski BF 2, Agata Szulc BF 3
DOI: 10.12659/MSM.948302
Med Sci Monit 2025; 31:e948302
Introduction
Methodology
Clinical Applications
Conditions for Conducting the Session
Summary of Current Knowledge on the Course of Psychedelic Psychotherapy
Safety and Ethical Considerations
Key Conclusions on Psychedelic-Assisted Psychotherapy and Navigating the Future of Psychedelic-Assisted Therapy: Research, Ethics, and Clinical Practice
References
Table 2 Possible clinical applications of selected substances in psychedelic-assisted psychotherapy.
| Depression | Anxiety disorders | PTSD | SUD | OCD | Nicotine dependence | |
|---|---|---|---|---|---|---|
| LSD | + | + | ||||
| Psylocybin | + | |||||
| MDMA | + | + | ||||
| Ketamine | + | + | + | |||
| DMT – N,N-dimethyltryptamine; LSD – d-lysergic acid diethylamide; MDMA – 3,4-methylenedioxymethamphetamine; OCD – obsessive-compulsive disorder; PTSD – post-traumatic stress disorder; SUD – substance use disorders. | ||||||